TILT Biotherapeutics to Collaborate with Merck KGaA and Pfizer

TILT Biotherapeutics Ltd. has entered into an agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate its armed oncolytic virus, TILT-123, with avelumab in patients with solid tumors refractory to routine modalities.
 
"We are pleased to initiate a collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to translate our findings into patients. Preclinical results with TILT®-technology and anti-PD(L)1 agents suggest immune activation and efficacy in certain animal models," said Akseli Hemminki chief executive officer and founder of TILT Biotherapeutics.
 
Avelumab is currently under clinical investigation in combination with TILT-123 for treatment of solid tumors and has not been demonstrated to be safe and effective for this use. 

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com